Abrocitinib Production Approval

Release date: 2024-07-09 14:54:49     Article From: Lucius Laos     Recommended: 114

02L1061_24 阿布昔替尼批文_00.jpg

CIBINQO is suitable for the treatment of refractory moderate to severe atopic dermatitis. Abuxitinib tablets belong to Janus kinase 1 inhibitors and are an oral Class 1 innovative drug. It reversibly and selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site, thereby exerting its pharmacological effects.

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.

Contact US

Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos

E-mail:laoslucius@gmail.com

Whatsapp:

ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved

whatsapp